"Hepatitis C (HCV) treatment is not a "one size fits all".
During the past ten years, there has been a remarkable increase in the number and spectrum of medications used for the treatment of viral hepatitis infections including the hepatitis C virus infection (HCV). Still there is considerable variability among physicians in the use and duration of treatment of the currently available medications. Therefore, the current literature on the HCV therapy will be reviewed and summarized.
American College of Gastroenterology (ACG), Morgantown, USA.
Faisal A
FA
Bukeirat
Mimi M
MM
Bukeirat
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008111:Liver Function Tests; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a